Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background The most suitable antihypertensive drug to reduce the risk of cardiovascular disease in patients with hypertension and diabetes is unclear. In prespecified analyses, we compared the effects of losartan and atenolol on cardiovascular morbidity and mortality in diabetic patients.Methods As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of left-ventricular hypertrophy (LVH) on electrocardiograms losartan-based or atenolol-based treatment. Mean age of patients was 67 years (SD 7) and mean blood pressure 177/96 mm Hg (14/10) after placebo run-in. We followed up patients for at least 4 years (mean 4.7 years [1.1]). We used Cox regression analysis with baseline Framingham risk score and electrocardiogram-LVH as covariates to compare the effects of the drugs on the primary composite endpoint of cardiovascular morbidity and mortality (cardiovascular death, stroke, or myocardial infarction).Findings Mean blood pressure fell to 146/79 mm Hg (17/11) in losartan patients and 148/79 mm Hg (19/11) in atenolol patients. The primary endpoint occurred in 103 patients assigned losartan (n=586) and 139 assigned atenolol (n=609); relative risk 0.76 (95% CI 0.58-.98), p=0.031. 38 and 61 patients in the losartan and atenolol groups, respectively, died from cardiovascular disease; 0.63 (0.42-0.95), p=0.028. Mortality from all causes was 63 and 104 in losartan and atenolol groups, respectively; 0.61 (0.45-0.84), p=0.002.Interpretation Losartan was more effective than atenolol in reducing cardiovascular morbidity and mortality as well as mortality from all causes in patients with hypertension, diabetes, and LVH. Losartan seems to have benefits beyond blood pressure reduction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All available BP-lowering drugs can be used, but evidence strongly supports using a renin-angiotensin system (RAS) inhibitor (ACE-I, ARB), particularly in patients with evidence of end-organ damage (albuminuria and left ventricular [LV] hypertrophy).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [213]
In the citing paper
“In patients with congestive heart failure (CHF), including diabetic subgroups, ARBs have been shown to reduce major CVD outcomes (175–178), and in type 2 patients with significant nephropathy, ARBs were superior to calcium channel blockers for reducing heart failure (179–181).”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [178]
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Self-citationDahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Self-citationStamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
(1999) · Journal of Hypertension · doi:10.1097/00004872-199917020-00001 · Cited by 3,695
(2000) · PubMed · Cited by 2,095
Research works printed but not linked: 2
- Liu, 2000, Cardiovascular disease and prognosis in adults with glucose disorders: the Strong Heart Study, J Am Coll Cardiol, 35, 263A
- 2002, Diabetic nephropathy, Diabetes Care, 25, S85
Cited by
Items 401–500 of 1,001
Syndrome métabolique : quelle définition pour quel(s) traitement(s) ?
Junquero, D. C., & Rival, Y. (2005) · médecine/sciences · doi:10.1051/medsci/200521121045 · Cited by 64
Efficacy of Angiotensin Receptor Blockers in Cardiovascular Disease
Maggioni, A. P. (2006) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-006-9799-9 · Cited by 38
On improving research methodology in clinical trials
Berger, V. W., Matthews, J. R., & Grosch, E. N. (2007) · Statistical Methods in Medical Research · doi:10.1177/0962280207080639 · Cited by 36
Treatment of hypertension and prevention of ischemic stroke
Aronow, W. S., & Frishman, W. H. (2004) · Current Cardiology Reports · doi:10.1007/s11886-004-0010-2 · Cited by 36
Are calcium antagonists beneficial in diabetic patients with hypertension?
Grossman, E., & Messerli, F. H. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.07.015 · Cited by 37
Type 2 Diabetes Mellitus and Heart Failure
Choy, C. K., Rodgers, J. E., Nappi, J. M., & Haines, S. T. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.2.170 · Cited by 36
Management of Hypertension in Diabetes
Stults, B. M., & Jones, R. E. (2006) · Diabetes Spectrum · doi:10.2337/diaspect.19.1.25 · Cited by 48
Best Strategies for Hypertension Management in Type 2 Diabetes and Obesity
Allcock, D. M., & Sowers, J. R. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0100-z · Cited by 35
Lin, Y., Wang, H., Tsai, M., Su, Y.-Y., Yang, M., & Chien, C. (2021) · Cancer · doi:10.1002/cncr.33391 · Cited by 35
Sugar and Stroke: Cerebrovascular Disease and Blood Glucose Control
Quinn, T. J., Dawson, J., & Walters, M. R. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00166.x · Cited by 38
Ding, W. Q., Wang, F., Fang, Q., Zhang, M., Chen, J., & Gu, Y. (2011) · Molecular Biology Reports · doi:10.1007/s11033-011-0862-7 · Cited by 36
Cardiovascular disease in patients who have diabetes
Goldberg, R. B. (2003) · Cardiology Clinics · doi:10.1016/s0733-8651(03)00074-2 · Cited by 43
Matsumoto, T., Ishida, K., Nakayama, N., Taguchi, K., Kobayashi, T., & Kamata, K. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.03.003 · Cited by 39
Silent Ischemia in People With Diabetes: A Condition That Must Be Heard
Tabibiazar, R., & Edelman, S. V. (2003) · Clinical Diabetes · doi:10.2337/diaclin.21.1.5 · Cited by 45
Loss of Heparan N-Sulfotransferase in Diabetic Liver
Williams, K. J., Liu, M.-L., Zhu, Y., Xu, X., Davidson, W. R., McCue, P., & Sharma, K. (2005) · Diabetes · doi:10.2337/diabetes.54.4.1116 · Cited by 31
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis
Lonn, E. (2002) · Current Atherosclerosis Reports · doi:10.1007/s11883-002-0074-7 · Cited by 56
Yazdanpanah, M., Aulchenko, Y. S., Albert Hofman, D., Janssen, J. A. M. J. L., Sayed‐Tabatabaei, F. A., van Schaik, R. H. N., Klungel, O. H., Stricker, B. H. C., Pols, H. A. P., Witteman, J. C. M., et al. (2007) · Diabetes · doi:10.2337/db06-1127 · Cited by 34
Brown, A., Lang, C. C., McCrimmon, R. J., & Struthers, A. D. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0663-6 · Cited by 35
Lin, M., Yuan, W., Su, Z., Lin, C., Huang, T., Chen, Y., & Wang, J. (2018) · Cell Proliferation · doi:10.1111/cpr.12517 · Cited by 38
Rosen, A. B. (2006) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2006.00351.x · Cited by 36
Manolis, A. J., Iraklianou, S., Pittaras, A. E., Zairis, M. N., Tsioufis, K. P., Psaltiras, G., PSOMALI, D., Foussas, S. G., Gavras, H. P., & Gavras, H. P. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.08.014 · Cited by 39
Pharmacist‐Led Cardiac Risk Reduction Model
Taveira, T. H., Wu, W., Martin, O. J., Schleinitz, M. D., Friedmann, P. D., & Sharma, S. C. (2006) · Preventive Cardiology · doi:10.1111/j.1520-037x.2006.05339.x · Cited by 37
Siebenhofer, A., Plank, J., Horvath, K., Berghold, A., Sutton, A. J., Sommer, R., & Pieber, T. R. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01122.x · Cited by 38
Ferrari, P. (2007) · Nephrology · doi:10.1111/j.1440-1797.2006.00749.x · Cited by 35
Interplay of diabetes and coronary heart disease on cardiovascular mortality: Table 1
Boccara, F., & Cohen, A. A. (2004) · Heart · doi:10.1136/hrt.2004.035766 · Cited by 32
Salvador, G. L. O., Marmentini, V. M., Cosmo, W. R., & Emilton, L. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317728766 · Cited by 36
Kovell, L. C., Juraschek, S. P., & Russell, S. D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0132228 · Cited by 33
Prediabetes: a must to recognise disease state
Shehab-Eldin, W. A., Emara, M., & Shoker, A. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01705.x · Cited by 40
Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM)
Souto, S. B., Souto, E. B., Braga, D. C., & Medina, J. L. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1038-z · Cited by 37
Zhang, H., Jiang, Y., Wen, J., Zhou, T., Fan, G., & Wu, Y. (2009) · Journal of Chromatography B · doi:10.1016/j.jchromb.2009.08.028 · Cited by 34
Ishida, K., Matsumoto, T., Taguchi, K., Kamata, K., & Kobayashi, T. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00502.2011 · Cited by 33
Ribeiro, A. B. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x75041 · Cited by 34
The prevention of type 2 diabetes mellitus: recent advances
Younis, N., Soran, H., & Farook, S. (2004) · QJM · doi:10.1093/qjmed/hch077 · Cited by 40
Volpe, M., Tocci, G., & Pagannone, E. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005121334 · Cited by 34
Cardiovascular complications in the diabetic patient with renal disease: an update in 2003
Dikow, R. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg253 · Cited by 32
Boger-Megiddo, I., Heckbert, S. R., Weiss, N. S., McKnight, B., Furberg, C. D., Wiggins, K. L., Delaney, J. A., Siscovick, D. S., Larson, E. B., Lemaître, R. N., et al. (2010) · BMJ · doi:10.1136/bmj.c103 · Cited by 34
Race-based therapy for hypertension: possible benefits and potential pitfalls
Ferdinand, K. C., & Ferdinand, D. P. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.10.1357 · Cited by 32
Dorenkamp, M., Riad, A., Stiehl, S., Spillmann, F., Westermann, D., Du, J., Pauschinger, M., Noutsias, M., Adams, V., Schultheiss, H., et al. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.07.020 · Cited by 33
Diabetes and Heart Disease: An Evidence-Driven Guide to Risk Factors Management in Diabetes
Lteif, A. A., Mather, K. J., & Clark, C. M. (2003) · Cardiology in Review · doi:10.1097/01.crd.0000086892.07437.05 · Cited by 39
Calkin, A. C., & Allen, T. J. (2006) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200606010-00003 · Cited by 36
New approaches in the intensive management of cardiovascular risk in the metabolic syndrome
Rosenson, R. S. (2005) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2004.10.001 · Cited by 35
Mazzone, T. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.02.003 · Cited by 33
Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997–2003
Chiang, C., Chen, C., Chiu, H., Wu, H., & Yang, C. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1322 · Cited by 32
Jugdutt, B. I., & Menon, V. (2004) · Molecular and Cellular Biochemistry · doi:10.1023/b:mcbi.0000026062.29029.d4 · Cited by 31
Naritomi, H., Fujita, T., Ito, S., Ogihara, T., Shimada, K., Shimamoto, K., Tanaka, H., & Yoshiike, N. (2008) · Hypertension Research · doi:10.1291/hypres.31.295 · Cited by 39
Type 2 diabetes mellitus: prevention of macrovascular complications
Meeuwisse-Pasterkamp, S. H., van der Klauw, M. M., & Wolffenbuttel, B. H. R. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.3.323 · Cited by 39
Diabetes mellitus and cerebrovascular disease: which are the actual data?
Hatzitolios, A. I., Didangelos, T., Zantidis, A., Τζιόμαλος, Κ., Giannakoulas, G. A., & Karamitsos, D. T. (2008) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2008.01.004 · Cited by 37
Oxidative Stress in Insulin-Resistant Conditions: Cardiovascular Implications
Stump, C. S., Clark, S. E., & Sowers, J. R. (2005) · Treatments in Endocrinology · doi:10.2165/00024677-200504060-00003 · Cited by 36
Kohlmann, O., Oigman, W., Mion, D., da Rocha, J. C., Gomes, M. A. M., Salgado, N., Feitosa, G. S., Dallaverde, E., & Ribeiro, A. B. (2006) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2006000100007 · Cited by 36
Beyond Blood Pressure: Pulse Wave Analysis – A Better Way of Assessing Cardiovascular Risk?
Davies, J. I., & Struthers, A. D. (2005) · Future Cardiology · doi:10.1517/14796678.1.1.69 · Cited by 34
Willemsen, J. M., Westerink, J., Dallinga‐Thie, G. M., van Zonneveld, A. J., Gaillard, S., Rabelink, T. J., & de Koning, E. J. P. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31802b31a7 · Cited by 32
Prediabetes: To treat or not to treat?
Moutzouri, E., Tsimihodimos, V., Rizos, E. C., & Elisaf, M. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.10.007 · Cited by 36
van der Veer, S. N., Biesen, W. V., Couchoud, C., Tomson, C., & Jager, K. J. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft473 · Cited by 33
Eplerenone improves vascular function and reduces platelet activation in diabetic rats.
Schäfer, A., Vogt, C., Fraccarollo, D., Widder, J., Flierl, U., Hildemann, S. K., Ertl, G., & Bauersachs, J. K. (2010) · PubMed · Cited by 30
Tocci, G., Presta, V., Ferri, C., Redón, J., & Volpe, M. (2020) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-020-00359-0 · Cited by 31
Geng, D.-F., Jin, D., Wu, W., Xu, Y., & Wang, J. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.10.011 · Cited by 33
Stabilized incidence of diabetic patients referred for renal replacement therapy in Denmark
Sørensen, V. R., Hansen, P. M., Heaf, J. G., & Feldt‐Rasmussen, B. (2006) · Kidney International · doi:10.1038/sj.ki.5001516 · Cited by 35
Phillips, B. A., Caspi, O., Murthy, G. D., & Nelson, M. R. (2009) · Cited by 29
Jugdutt, B. I., & Menon, V. (2004) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(03)00584-0 · Cited by 31
Murray, C. M., & Shah, B. R. (2015) · Primary care diabetes · doi:10.1016/j.pcd.2015.10.007 · Cited by 35
Motwani, J. G. (2002) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2002.021 · Cited by 34
Cram, P. M., Vijan, S. S., Katz, D. A., & Fendrick, A. M. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.40247.x · Cited by 30
Foley, R. N. (2004) · Seminars in Dialysis · doi:10.1111/j.0894-0959.2004.17326.x · Cited by 32
(ESC), G. D. T. S. D. Y. E. C. D. L. S. E. D. C., & (EASD), D. L. S. E. P. E. E. D. L. D. (2007) · Revista Española de Cardiología · doi:10.1016/s0300-8932(07)75070-4 · Cited by 30
Sharma, A., BAGCHI, A., Kinagi, S., Sharma, Y. B., Baliga, V. P., & Bolmall, C. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.12.017 · Cited by 29
Emerging drugs which target the renin–angiotensin–aldosterone system
Steckelings, U. M., Paulis, L., Unger, T., & Bäder, M. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.618495 · Cited by 31
Management of Hypertension in the Elderly Population
Oliva, R., & Bakris, G. L. (2012) · The Journals of Gerontology Series A · doi:10.1093/gerona/gls148 · Cited by 30
Human cell receptors: potential drug targets to combat COVID-19
Raghav, P. K., Kalyanaraman, K., & Kumar, D. (2021) · Amino Acids · doi:10.1007/s00726-021-02991-z · Cited by 32
Oparil, S., & Weber, M. A. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.03.1974 · Cited by 33
Self-citationDiscovery of Novel GPVI Receptor Antagonists by Structure-Based Repurposing
Taylor, L., Vasudevan, S. R., Jones, C. I., Gibbins, J. M., Churchill, G. C., Campbell, R. D., & Coxon, C. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101209 · Cited by 35
Cardiac hypertrophy as a target of antihypertensive therapy
Zanchetti, A. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.229 · Cited by 29
Primary Prevention of Heart Failure
Butler, J. (2012) · ISRN Cardiology · doi:10.5402/2012/982417 · Cited by 37
Inhibiting angiotensin type 1 receptors as a target for diabetes
Kintscher, U., Foryst‐Ludwig, A., & Unger, T. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.10.1257 · Cited by 31
Beta blockers in patients with end‐stage renal disease—Evidence‐based recommendations
Weir, M. A., & Herzog, C. A. (2018) · Seminars in Dialysis · doi:10.1111/sdi.12691 · Cited by 32
Appel, G. B., & Appel, A. S. (2004) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2004.04.005 · Cited by 29
Comparative Effects of Irbesartan on Ambulatory and Office Blood Pressure
Rossing, K., Christensen, P. K., Andersen, S., Hovind, P. H., Hansen, H. P., & Parving, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.569 · Cited by 29
Awareness, treatment and control of hypertension in Denmark. The Inter99 study
Sehestedt, T. B., Ibsen, H., & Jørgensen, T. (2007) · Blood Pressure · doi:10.1080/08037050701428307 · Cited by 28
Self-citationLong-term safety of antihypertensive therapy
Grossman, E., & Messerli, F. H. (2006) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2006.06.002 · Cited by 30
McFarlane, S. I., Shin, J. J., Rundek, T., & Bigger, J. T. (2003) · Current Diabetes Reports · doi:10.1007/s11892-003-0070-5 · Cited by 28
Wu, P.-Y., Huang, C., Lei, W., & Yang, S. (2015) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.12317 · Cited by 35
Diabetic Cardiovascular Disease: Getting to the Heart of the Matter
Peterson, L. R., McKenzie, C. R., & Schaffer, J. E. (2012) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9374-7 · Cited by 33
Mullen, M., Flather, M. D., Jin, X. Y., Newman, W. G., Erdem, G., Gaze, D. C., Valencia, O., BANYA, W. A. S., Foley, C. E., & Child, A. H. (2013) · Trials · doi:10.1186/1745-6215-14-408 · Cited by 30
Partial Peroxisome Proliferator-Activated Receptor Agonist Angiotensin Receptor Blockers
Towfighi, A., & Ovbiagele, B. I. (2008) · Cerebrovascular Diseases · doi:10.1159/000139656 · Cited by 28
Telmisartan inhibits methylglyoxal-mediated cell death in human vascular endothelium
Baden, T., Yamawaki, H., Saito, K., Mukohda, M., Okada, M., & Hara, Y. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.06.023 · Cited by 28
Metabolic Syndrome and Prediabetes
Babu, A. R., & Fogelfeld, L. A. (2006) · Disease-a-Month · doi:10.1016/j.disamonth.2006.03.001 · Cited by 29
The effect of polymorphisms in the renin–angiotensin–aldosterone system on diabetic nephropathy risk
Möllsten, A., Kockum, I. S., Svensson, M. K. E., Rudberg, S. L., Ugarph-Morawski, A., Brismar, K., Eriksson, J. W., & Dahlquist, G. G. (2008) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2007.06.005 · Cited by 28
Nosadini, R., & Tonolo, G. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000034687.62568.9b · Cited by 31
Choice of anti-hypertensive agents in diabetic subjects
Patel, B. M., & Mehta, A. A. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164113485250 · Cited by 33
A review of nateglinide in the management of patients with type 2 diabetes.
Tentolouris, N., Voulgari, C., & Katsilambros, N. L. (2007) · PubMed Central · Cited by 50
Modulation of Cardiovascular Remodeling with Statins: Fact or Fiction?
Reddy, R., Chahoud, G., & Mehta, J. L. (2005) · Current Vascular Pharmacology · doi:10.2174/1570161052773915 · Cited by 32
Martin, J. H., & Krum, H. (2002) · Pharmacological Research · doi:10.1016/s1043-6618(02)00092-0 · Cited by 28
Heart Failure—The Importance of Ethnicity
Sosin, M. D., Bhatia, G. S., Davis, R., & Lip, G. Y. H. (2004) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2003.11.019 · Cited by 32
Julius, S. (2003) · Journal of Hypertension · doi:10.1097/00004872-200303000-00001 · Cited by 28
Self-citationEffect of β‐Blockers Beyond 3 Years After Acute Myocardial Infarction
Park, J. J., Kim, S., Kang, S., Yoon, C., Cho, Y., Youn, T., Chae, I., & Choi, D. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007567 · Cited by 31
Zhang, Y., Ding, X., Hua, B., Liu, Q., Chen, H., Zhao, X.-Q., Li, W., & Li, H. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02314-y · Cited by 30
Matsumoto, T., Ishida, K., Taguchi, K., Kobayashi, T., & Kamata, K. (2010) · Journal of Pharmacological Sciences · doi:10.1254/jphs.09308fp · Cited by 30
DePaula, A. L., Stival, A. R., DePaula, C. C. L., Halpern, A., & Vencio, S. A. C. (2010) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-010-1252-5 · Cited by 27
Vascular Complications of Diabetes Mellitus
Chiong, Y., & Evans‐Molina, C. (2014) · Springer eBooks · doi:10.1007/978-3-642-37078-6_49 · Cited by 31
Moen, M. D., & Wagstaff, A. J. (2005) · Drugs · doi:10.2165/00003495-200565180-00012 · Cited by 33
Eijkelkamp, W. B. A., Zhang, Z., Brenner, B. M., Cooper, M. E., Devereux, R. B., Dahlöf, B., Ibsen, H., Keane, W. F., Lindholm, L. H., Olsen, M. H., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e328014953c · Cited by 27
Self-citation
Metadata
- Authors
- Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., Lederballe-Pedersen, O., Nieminen, M. S., Omvik, P., Oparil, S., Wedel, H., Aurup, P., Edelman, J., & Snapinn, S.
- Affiliations
- University Hospital of Umeå (SE)
- Glostrup Hospital (DK)
- Sahlgrenska University Hospital (SE)
- Birmingham City Hospital (GB)
- Helsinki University Hospital (FI)
- University of Michigan (US)
- Oslo University Hospital (NO)
- Haukeland University Hospital (NO)
- University of Alabama at Birmingham (US)
- Nordic School of Public Health (SE)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Lindholm, Lars H
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2002-03
- Volume
- 359
- Issue
- 9311
- Pages
- 1004-1010
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W1982920623
- Cited by
- 1,560
- References
- 31
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 8 · 2023: 15 · 2022: 17 · 2021: 18 · 2020: 29 · 2019: 16 · 2018: 28 · 2017: 40 · 2016: 40 · 2015: 41 · 2014: 48 · 2013: 58 · 2012: 58
- FWCI
- 129.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- losartan, atenolol, hypertension, diabetes mellitus, left ventricular hypertrophy, cardiovascular morbidity, cardiovascular mortality, antihypertensive drugs, ACE inhibitors, beta-blockers, LIFE trial, stroke, myocardial infarction, all-cause mortality, blood pressure reduction, Framingham risk score, electrocardiogram
- MeSH terms
- Aged, Aged, 80 and over, Antihypertensive Agents, Atenolol, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypertension, Male, Middle Aged, Regression Analysis, Losartan, Diabetes Complications, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.